Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and chronic P. aeruginosa infections.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aradigm Corporation
• Collaborators: Grifols Therapeutics Inc.; Grifols Therapeutics LLC
• Treatments: Ciprofloxacin

Criteria

Inclusion Criteria:

• Verified bronchiectasis diagnosis

• Pseudomonas aeruginosa lung infection

Exclusion Criteria:

• Cystic Fibrosis